Hemopressin Peptides and WIN Showed Symmetrical Cross-Tolerance After Direct Brain Administration in Mice

A mouse study found antinociceptive tolerance and symmetrical cross-tolerance among hemopressin, VD-hemopressin alpha and WIN55,212-2. The finding applies to direct supraspinal administration and a thermal response, rather than every effect of these ligands.

The ligands carried different pharmacological descriptions

Hemopressin had been characterized as a CB1 antagonist or inverse agonist, while its extended peptide was described as an agonist. Nevertheless, hemopressin produced dose-dependent antinociception after intracerebroventricular administration. A receptor label alone did not settle its observed effect in this protocol.

Repeated exposure reduced the response

Tolerance developed by the fourth treatment day for each of the three ligands. Cross-challenges showed symmetrical cross-tolerance among them on the radiant-heat tail-flick measure. This supports overlap in adaptation under the tested conditions without demonstrating identical molecular actions.

A common mechanism was an inference

The authors interpreted the shared pattern as implying a common antinociceptive mechanism. Cross-tolerance alone cannot specify every receptor interaction or exclude downstream convergence. Nor does symmetry on one thermal endpoint imply symmetry for temperature, movement, reward or other functions.

The study adds an experimentally defined relationship between cannabinoid-related peptides and a synthetic agonist. Direct brain administration and mouse antinociception sharply limit clinical translation. It does not establish oral efficacy, human safety or a method of predicting cannabis impairment.

Related: interpreting cannabis tolerance claims.

Research cited

Pan JX; Wang ZL; Li N; Han ZL; Li XH; Tang HH; Wang P; Zheng T; Fang Q; Wang R. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice. Neuroscience letters (2014). doi:10.1016/j.neulet.2014.06.058. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Rat THC–Alcohol Study Found Cross-Tolerance Without Faster Drug Disappearance

A 1979 female-rat study found THC-to-alcohol cross-tolerance on a coordination task without evidence that faster drug disappearance explained the result. The reverse direction was incomplete, so the two exposure histories were not equivalent. The challenge doses were matched by behavioral effect Acute THC and ethanol challenges were selected to reduce…

Spread the love

Read Article: A Rat THC–Alcohol Study Found Cross-Tolerance Without Faster Drug Disappearance

Behavioral THC Tolerance Did Not Eliminate Antibody-Response Suppression in Rats

A 1980 rat study reported behavioral tolerance during oral THC treatment without tolerance to suppression of selected antibody-related responses. The timing of THC relative to antigen exposure also changed the immune result. The immune challenge was experimentally defined Rats received oral THC or vehicle around an antigenic challenge with sheep…

Spread the love

Read Article: Behavioral THC Tolerance Did Not Eliminate Antibody-Response Suppression in Rats

Matched Food-Delivery Schedules Still Produced Different THC Adaptation Patterns in Monkeys

A 1980 squirrel-monkey experiment matched baseline food-delivery patterns yet found schedule-dependent adaptation to THC. The findings offered only partial support for the idea that reinforcement loss alone explains behavioral tolerance. Two response rules produced comparable baseline rewards One component required a long interval between responses, while another used a modified…

Spread the love

Read Article: Matched Food-Delivery Schedules Still Produced Different THC Adaptation Patterns in Monkeys

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us